---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-088661"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:23:03.424360+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharma: Phase 3 RAPID PSVT trial reaches 180 events; topline data on track for mid-H2 2022

## Summary
- Q2 2022 operating loss $16.8M vs income $0.7M prior year due to $15M one-time revenue from Ji Xing in 2021; cash $86.2M.
- RAPID Phase 3 PSVT trial achieved target of 180 confirmed events; topline data expected mid-second half 2022.
- Ji Xing enrolled first patient in Phase 3 etripamil study in China; data may support NDA in China.
- NODE-302 open-label extension data showed 60.2% PSVT conversion at 30 min; 8.5% ED intervention rate.
- R&D expense $10.7M in Q2 2022, up from $9.4M due to RAPID trial advancement.

## SEC filing metadata
- accession: 0001104659-22-088661
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465922088661/0001104659-22-088661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465922088661/tm2223120d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-088661
- JSON: https://secwatch.observer/filing/0001104659-22-088661.json
- Plain text: https://secwatch.observer/filing/0001104659-22-088661.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.